For many people with severe vision loss, regular eye tests do not tell the whole story. When vision becomes very limited, it can be hard for doctors to measure what someone can still see. To help solve this problem, researchers developed a special test called full field stimulus testing, or FST, about 20 years ago. This test was designed to measure how well the retina is working, even when vision is very low. Today, FST is widely used by researchers studying inherited vision loss and new treatments like gene therapy.
Scientists wanted to make sure FST truly measured vision correctly. In a study of more than 200 people with various inherited eye conditions, researchers confirmed that FST measures vision based on the most sensitive parts of the retina. They also tested a concern that hidden light-sensing cells might affect the results, but this idea was proven false. These findings showed that FST is a dependable tool.
FST has already been used to follow vision changes in people who received gene therapy for Leber congenital amaurosis, another inherited eye disease. The test was able to show real improvements in vision that matched what patients noticed in their everyday lives.
What this means for the Usher syndrome community: For people with Usher syndrome, FST offers a reliable way to measure vision when standard tests are not enough. This is important for future gene therapy studies because it helps researchers clearly see whether new treatments are making a difference.
